Expertise in
27
conditions

Dr. Joseph Uberti

Oncology
Office
4100 John R St, 
Detroit, MI 
45 Years of Experience
Expertise in
27
conditions
Office
4100 John R St, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Uberti is an Oncologist in Detroit, Michigan. Dr. Uberti has been practicing medicine for over 45 years is highly rated in 27 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Karmanos Cancer Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Office
4100 John R St, Detroit, MI 48201
Other Locations
University Physician Group
1560 E Maple Rd, Troy, MI 48083

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
Enrollment Status: Terminated
Publish Date: January 12, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2/Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors After Hematopoietic Cell Transplantation
INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors After Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Unknown
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination
Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Biological, Other
Study Drugs: HER2Bi-Armed Activated T Cells, Pembrolizumab
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 3
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Enrollment Status: Terminated
Publish Date: December 17, 2020
Intervention Type: Other, Drug
Study Phase: Phase 1
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Behavioral
Phase I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Phase I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Enrollment Status: Terminated
Publish Date: March 16, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

77 Total Publications

Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial.
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial.
Journal: Transplantation and cellular therapy
Published: December 04, 2025
Similar Doctors
Shirish M. Gadgeel
Expertise in
15
conditions
Dr. Shirish M. Gadgeel
Oncology | Hematology | Hematology Oncology
Expertise in
15
conditions
Dr. Shirish M. Gadgeel
Oncology | Hematology | Hematology Oncology

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (1.8 miles away)
313-916-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shirish Gadgeel is an Oncologist and a Hematologist in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Gadgeel is currently accepting new patients.

Expertise in
5
conditions
Dr. Emily Meier
Hematology | Oncology
Expertise in
5
conditions
Dr. Emily Meier
Hematology | Oncology

DMC Children's Hospital Of Michigan

3901 Beaubien St, 
Detroit, MI 
 (0.1 miles away)
313-745-5437
Languages Spoken:
English
See accepted insurances

Emily Meier is a Hematologist and an Oncologist in Detroit, Michigan. Dr. Meier is highly rated in 5 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

Expertise in
15
conditions
Dr. Anthony F. Shields
Hematology Oncology | Hematology | Oncology
Expertise in
15
conditions
Dr. Anthony F. Shields
Hematology Oncology | Hematology | Oncology

University Physician Group

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
800-527-6266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anthony Shields is a Hematologist Oncology specialist and a Hematologist in Detroit, Michigan. Dr. Shields is highly rated in 15 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Anal Cancer, and Neuroendocrine Tumor. Dr. Shields is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Uberti's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 15 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile